John P. Schmid
CIK 1478916 · Chief Financial Officer · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.36M
Companies
9
Total Filings
83
Lifetime Open-Market Net
-$1.09M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ANAB | Director | 37,652 | $52.11 | $1.96M | -$1.16M | 18 | 2026-06-17 |
| TRAX | Director | 37,652 | $41.85 | $1.58M | $0 | 4 | 2026-06-17 |
| DSGN | Director | 57,639 | $11.87 | $684.2K | $99.7K | 7 | 2026-06-11 |
| BridgeBio Oncology Therapeutics, Inc. (HLXB) Delisted | 30,000 | $9.90 | $297.0K | $0 | 1 | 2025-08-11 | |
| Poseida Therapeutics, Inc. (PSTX) Delisted | Director | 0 | $9.50 | $0 | $0 | 7 | 2025-01-08 |
| XERS | Director | 138,359 | $8.24 | $1.14M | $50.1K | 12 | 2024-08-13 |
| Neos Therapeutics, Inc. (NEOS) Delisted | Director | 0 | $1.15 | $0 | $0 | 6 | 2021-03-19 |
| Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Chief Financial Officer | 0 | — | — | $0 | 2 | 2015-05-06 |
| Trius Therapeutics Inc (TSRX) Delisted | Chief Financial Officer | 107,639 | — | — | -$85.0K | 23 | 2013-03-11 |
Recent Filings · Page 3 of 9
83 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-18 | ANAB | Exer (M) | +3,900 | $0 | EDGAR |
| 2024-06-18 | Poseida Therapeutics, Inc. (PSTX) Delisted | Grant (A) | +19,650 | $0 | EDGAR |
| 2024-06-17 | DSGN | Grant (A) | — | $0 | EDGAR |
| 2024-06-05 | XERS | Grant (A) | +50,000 | $0 | EDGAR |
| 2024-05-10 | XERS | Buy (P) | +5,400 | $10.3K | EDGAR |
| 2024-03-25 | DSGN | Buy (P) | +26,965 | $99.7K | EDGAR |
| 2024-03-14 | XERS | Buy (P) | +4,500 | $9.7K | EDGAR |
| 2024-01-05 | ANAB | Grant (A) | — | $0 | EDGAR |
| 2023-11-17 | XERS | Buy (P) | +6,500 | $9.8K | EDGAR |
| 2023-06-16 | Poseida Therapeutics, Inc. (PSTX) Delisted | Grant (A) | +19,650 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.